Lundbeck doubled its offer for Longboard over six months, new filing showsnews2024-10-30T14:30:56+00:00October 30th, 2024|Endpoints News|
Biogen signs molecular glue deal, raises yearly projectionsnews2024-10-30T11:26:16+00:00October 30th, 2024|Endpoints News|
Novartis highlights overall M&A track record following MorphoSys impairmentnews2024-10-29T17:02:34+00:00October 29th, 2024|Endpoints News|
GSK buys autoimmune T cell engager for $300M upfront from Chimagennews2024-10-29T14:48:34+00:00October 29th, 2024|Endpoints News|
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse mergernews2024-10-29T11:33:53+00:00October 29th, 2024|Endpoints News|
Corrected: Genmab lines up T cell engager pact with Revitopenews2024-10-29T11:15:59+00:00October 29th, 2024|Endpoints News|
Novartis takes $800M MorphoSys writedown mere months after closing acquisitionnews2024-10-29T11:04:41+00:00October 29th, 2024|Endpoints News|
AbbVie makes $1.4B acquisition of Alzheimer’s biotechnews2024-10-28T14:27:08+00:00October 28th, 2024|Endpoints News|
Novartis pays Monte Rosa $150M for Phase 1 drug in latest endorsement of molecular gluesnews2024-10-28T11:00:38+00:00October 28th, 2024|Endpoints News|
